William Blair analyst Myles Minter has reiterated their bullish stance on TRDA stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Myles Minter has given his Buy rating due to a combination of factors including Entrada Therapeutics Inc’s strategic focus on its Duchenne muscular dystrophy (DMD) franchise. The company’s recent clearance to begin the Phase I/II ELEVATE-44-201 trial for ENTR-601-44 in Europe marks a significant step forward. This trial, targeting exon 44 skipping in DMD patients, is expected to provide crucial data that could position Entrada favorably against competitors like Avidity.
Minter also highlights the broader pipeline developments as a positive indicator for the company. The initiation of the Phase I/II ELEVATE-201-45 trial for the exon 45 skipper, along with plans for future trials on exon 50 and 51 skippers, demonstrates a robust pipeline strategy. Additionally, the progress of the DMPK-targeting antisense oligonucleotide VX-670 in collaboration with Vertex further strengthens Entrada’s position in the market. These strategic initiatives collectively underpin Minter’s optimistic outlook on the company’s stock.
According to TipRanks, Minter is a 4-star analyst with an average return of 5.0% and a 48.62% success rate. Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Alnylam Pharma, and Arcturus Therapeutics.